HC Wainwright Estimates Valneva’s Q1 Earnings (NASDAQ:VALN)

Valneva SE (NASDAQ:VALN) – Research analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Valneva in a note issued to investors on Thursday, January 23rd. HC Wainwright analyst E. White anticipates that the company will earn ($0.38) per share for the quarter. HC Wainwright has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for Valneva’s current full-year earnings is $0.15 per share. HC Wainwright also issued estimates for Valneva’s Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.31) EPS and Q4 2025 earnings at ($0.31) EPS.

Valneva Stock Performance

Shares of NASDAQ:VALN opened at $4.90 on Friday. The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70. The company has a 50-day moving average price of $4.29 and a 200-day moving average price of $5.77. The company has a market cap of $398.17 million, a price-to-earnings ratio of -37.69 and a beta of 1.93. Valneva has a 12 month low of $3.62 and a 12 month high of $9.50.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Valneva stock. AlphaCentric Advisors LLC boosted its holdings in shares of Valneva SE (NASDAQ:VALN) by 33.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 118,000 shares of the company’s stock after acquiring an additional 29,748 shares during the period. AlphaCentric Advisors LLC owned 0.15% of Valneva worth $717,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.